Accuracy of 18F-FDG PET/CT for lymph node staging in non-small-cell lung cancers

Accuracy of 18F-FDG PET/CT for lymph node staging in non-small-cell lung cancers
复制标题

DOI:
10.3760/cma.j.issn.0366-6999.2009.15.006
复制
发表时间:
2009-08-05
影响因子:
6.1
通讯作者:
Cao Yu-xue
Cao Yu-xue
中科院分区:
医学2区
文献类型:
--
作者:
Liu Bao-jun;Dong Jing-cheng;Cao Yu-xue

文献摘要

被引文献

相似文献

本回顾性研究评估了2-(F18)-氟-2-脱氧-d -葡萄糖-正电子发射断层扫描(F-18-FDG-PET)/计算机断层扫描(PET/CT)在非小细胞肺癌(NSCLC)患者术前诊断转移性纵隔和肺门淋巴结的准确性。方法39例患者术前行F-18-FDG PET/CT检查,术后行活检。我们比较了39例非小细胞肺癌患者术前PET/CT扫描结果与术中相应的组织病理学结果。评估F-18-FDG PET/CT的敏感性、特异性、准确性、阳性预测值和阴性预测值。结果组织病理学检查证实,208例切除淋巴结中57例转移;57个淋巴结中有23个为纵隔淋巴结和肺门淋巴结。PET/CT术前诊断NSCLC患者纵隔淋巴结转移的敏感性、特异性、准确性、阳性预测值和阴性预测值分别为65%、96.8%、92%、78.5%和90%。结论PET/CT扫描对非小细胞肺癌纵隔及肺门淋巴结转移的术前诊断具有较好的准确性。我们建议将PET/CT扫描作为肿瘤诊断、治疗评估和随访的一线评估工具。
Background This retrospective study evaluated the diagnostic accuracy of 2-(F18)-fluoro-2-deoxy-D-glucose-positron emission tomography (F-18-FDG-PET)/computed tomography (PET/CT) in the preoperative diagnosis of metastatic mediastinal and hilar lymph node in patients with non-small-cell lung cancer (NSCLC).Methods A total of 39 patients received preoperative F-18-FDG PET/CT and the postoperative biopsy. We compared preoperative PET/CT scan results with corresponding intraoperative histopathalogic findings in 39 NSCLC patients. The sensitivity, specificity, accuracy, positive and negative predictive value of F-18-FDG PET/CT were assessed.Results Histopathologic examination confirmed metastasis in 57 out of the 208 excised lymph nodes; 23 of the 57 nodes were mediastinal and hilar lymph nodes. The sensitivity, specificity, accuracy, positive predictive value and negative predictive value of PET/CT in the preoperative diagnosis of mediastinal lymph node metastasis in NSCLC patients were 65%, 96.8%, 92%, 78.5% and 90%, respectively.Conclusions PET/CT scan showed good accuracy in the preoperative diagnosis of mediastinal and hilar lymph node metastasis in the patients with NSCLC. We recommend that PET/CT scanning be used as a first-line evaluation tool for tumor diagnosis, therapy evaluation and follow-up.